NEW YORK (GenomeWeb) – WaferGen Biosystems reported after the close of the market Thursday that its second quarter revenues rose over 600 percent and that its net loss was down 38 percent compared with the year-ago period.

The genetic analysis products maker reported total revenues of $1.7 million for the three months ended June 30, up from $246,248 in Q2 2013. The firm's product revenue was $1.7 million versus $121,248 year over year, while its license and royalty revenue remained flat for the quarter at $125,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.